Faculty Opinions recommendation of Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.738661668.793580989 ◽

2020 ◽

Author(s):

Richard Riedel

Keyword(s):

Preoperative Radiotherapy ◽

Retroperitoneal Sarcoma ◽

Open Label ◽

Phase 3 ◽

Primary Retroperitoneal

Download Full-text

Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30446-0 ◽

2020 ◽

Vol 21 (10) ◽

pp. 1366-1377 ◽

Cited By ~ 14

Author(s):

Sylvie Bonvalot ◽

Alessandro Gronchi ◽

Cécile Le Péchoux ◽

Carol J Swallow ◽

Dirk Strauss ◽

...

Keyword(s):

Preoperative Radiotherapy ◽

Retroperitoneal Sarcoma ◽

Open Label ◽

Phase 3 ◽

Primary Retroperitoneal

Download Full-text

Local control following resection of primary retroperitoneal sarcoma with and without preoperative radiotherapy.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.10572 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 10572-10572 ◽

Cited By ~ 2

Author(s):

Carol Jane Swallow ◽

Amanda Cannell ◽

Brendan Dickson ◽

Sally Burtenshaw ◽

Peter W. M. Chung ◽

...

Keyword(s):

Local Control ◽

Preoperative Radiotherapy ◽

Retroperitoneal Sarcoma ◽

Primary Retroperitoneal

Download Full-text

Featured Clinical Trial: Preoperative Radiotherapy for Retroperitoneal Sarcoma

PsycEXTRA Dataset ◽

10.1037/e481372006-006 ◽

2005 ◽

Author(s):

Keyword(s):

Clinical Trial ◽

Preoperative Radiotherapy ◽

Retroperitoneal Sarcoma

Download Full-text

EVOLVE-MS-1: a phase 3, open-label, long-term safety study of ALKS 8700 in relapsing-remitting multiple sclerosis

10.26226/morressier.59a3edabd462b8028d8952fe ◽

2017 ◽

Author(s):

Robert T. Naismith

Keyword(s):

Multiple Sclerosis ◽

Open Label ◽

Safety Study ◽

Phase 3 ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Faculty Opinions recommendation of Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1166102.628092 ◽

2009 ◽

Author(s):

Jim Orr ◽

Fadi Abu Shahin

Keyword(s):

Ovarian Cancer ◽

Randomised Controlled Trial ◽

Controlled Trial ◽

Advanced Ovarian Cancer ◽

Open Label ◽

Phase 3 ◽

Dose Dense ◽

Randomised Controlled

Download Full-text

Faculty Opinions recommendation of Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13827960.15267062 ◽

2012 ◽

Author(s):

Weijing Sun ◽

Davendra Sohal

Keyword(s):

Gastric Cancer ◽

Randomised Controlled Trial ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

D2 Gastrectomy ◽

Randomised Controlled

Download Full-text

Faculty Opinions recommendation of Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717958906.793462914 ◽

2012 ◽

Author(s):

Nelson Chao

Keyword(s):

Complete Remission ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Cell Transplantation ◽

Reduced Intensity Conditioning ◽

Open Label ◽

Phase 3 ◽

First Complete Remission ◽

Reduced Intensity ◽

Acute Myeloid

Download Full-text

Faculty Opinions recommendation of Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717955064.793462779 ◽

2012 ◽

Author(s):

Nancy Lin ◽

Ines Vaz-Luis

Keyword(s):

Breast Cancer ◽

Intravenous Administration ◽

Clinical Stage ◽

Randomised Trial ◽

Stage I ◽

Her2 Positive ◽

Open Label ◽

Phase 3 ◽

Adjuvant Trastuzumab

Download Full-text

Faculty of 1000 evaluation for Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.717976445.793471388 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

First Line Treatment

Download Full-text

Faculty Opinions recommendation of Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718006635.793477611 ◽

2013 ◽

Author(s):

Ian Beales

Keyword(s):

Gastric Cancer ◽

Advanced Gastric Cancer ◽

Open Label ◽

Phase 3 ◽

Open Label Phase

Download Full-text